The invention discloses a multi-technology combined medication analysis platform of an
oligonucleotide drug, which relates to the technical field of
drug analysis and is technically characterized by comprising an
oligonucleotide drug delivery technology module, a
liposome, a
polymer nanoparticle or an
exosome is selected as a delivery carrier, the surface of the delivery carrier is modified with hydrophilic
polyethylene glycol or a targeting ligand, and the
oligonucleotide drug delivery technology module is connected with the oligonucleotide
drug delivery module. The performance of the material is represented by
dynamic light scattering and a transmission
electron microscope; the multi-technology platform analysis module integrates RT-qPCR, LC-FL, LC-MS / MS and LC-HRMS technologies, is respectively used for
target gene expression quantification, drug distribution tracking, drug principal component quantification and
metabolite structure analysis, establishes a
cross validation rule, and requires a
correlation coefficient R2gt of an LC-MS / MS
quantitative result and RT-qPCR
expression data; 0.95%, 0.95%; the pharmacokinetic evaluation module constructs a PBPK model to predict human pharmacokinetic parameters, and draws a
drug metabolism network diagram in combination with an LC-HRMS
metabolite identification result; by integrating various advanced analysis technologies, the problems of low sensitivity, poor specificity and difficult
metabolite analysis in the prior art are solved.